Preface |
|
xxxi | |
Asia Regulatory Professional Association |
|
xxxiii | |
|
1 How to Train University Students in Regulatory Affairs |
|
|
1 | (6) |
|
|
|
1 | (1) |
|
1.2 A Sample of Regulatory Affairs Exercises for Students |
|
|
2 | (5) |
|
|
2 | (5) |
|
|
|
2 The Evolution of the Regulatory Professional: Perspectives on the Skill Sets and Capabilities That Will Define the Next Generation of Regulatory Professionals |
|
|
7 | (10) |
|
|
|
|
7 | (1) |
|
|
8 | (2) |
|
2.3 Historical Role and Skill Set of a Regulatory Professional |
|
|
10 | (2) |
|
2.4 Changing Role and Skill Set of the Regulatory Professional |
|
|
12 | (1) |
|
2.5 Develop as a Center of Intelligence |
|
|
12 | (1) |
|
2.6 Advance Toward Strategic Relationship Management |
|
|
13 | (1) |
|
2.7 Develop as a Strategic Business Partner |
|
|
13 | (1) |
|
2.8 Conclusion: What Will It Take to Get There? |
|
|
14 | (3) |
|
3 Ensuring Smooth Product Launch: Regulatory Interfaces with Marketing and Supply Chain |
|
|
17 | (4) |
|
|
|
17 | (1) |
|
|
18 | (1) |
|
|
18 | (1) |
|
3.4 New Product Forecasts |
|
|
19 | (1) |
|
3.5 New Product Approval Dates |
|
|
19 | (2) |
|
4 What Is the Right Thing to Do? |
|
|
21 | (4) |
|
|
|
21 | (1) |
|
4.2 Two Key Challenges in Our Job |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
4.3 Regulatory Affairs Job Is a Combination of Science, Legal Affairs, and Moral |
|
|
22 | (1) |
|
4.4 Persons versus Things |
|
|
22 | (3) |
|
5 Affordable Access to Medical Devices in Developing Countries |
|
|
25 | (10) |
|
|
|
|
25 | (1) |
|
5.2 Why Is Affordable Access to Medical Devices Important for Developing Countries? |
|
|
26 | (3) |
|
5.2.1 Emergency Preparedness |
|
|
27 | (1) |
|
5.2.2 Efficiency and Effectiveness of Health Systems |
|
|
27 | (1) |
|
|
28 | (1) |
|
|
29 | (4) |
|
5.3.1 Delay in Eligibility to Treatment for HIV |
|
|
29 | (1) |
|
5.3.2 Delay in Access to Early Diagnosis of Tuberculosis |
|
|
29 | (1) |
|
5.3.3 Misleading Claims of Test Performance for Dengue Rapid Tests |
|
|
30 | (1) |
|
5.3.4 Case Study --- Access versus Performance: Basis for FDA Approval of the First Over- the- Counter Rapid HIV Test in the United States |
|
|
31 | (1) |
|
|
31 | (1) |
|
5.3.4.2 Performance expectations |
|
|
31 | (1) |
|
5.3.4.3 Risk benefit analysis |
|
|
32 | (1) |
|
|
33 | (2) |
|
6 A Story of Attention to Detail |
|
|
35 | (4) |
|
|
PART 2 Medical Device Safety AND Related ISO Standards |
|
|
|
7 Biomedical Devices: Overview |
|
|
39 | (14) |
|
|
7.1 Historic Aspect of Medical Devices |
|
|
39 | (2) |
|
7.2 Biomedical Market Environment |
|
|
41 | (1) |
|
|
42 | (4) |
|
|
42 | (1) |
|
|
43 | (1) |
|
|
43 | (1) |
|
|
44 | (1) |
|
7.3.5 Polyethylene Fabrication |
|
|
44 | (2) |
|
|
46 | (2) |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
49 | (4) |
|
8 Labeling, Label, and Language: A Truly Global Matter |
|
|
53 | (14) |
|
|
|
|
53 | (2) |
|
8.2 Definition of Labeling |
|
|
55 | (1) |
|
|
56 | (3) |
|
8.4 Risk Management, Clinical Evaluation and Labeling: The Core Triangle for Safe and Effective Use of the Device |
|
|
59 | (1) |
|
8.5 Labeling and Promotion |
|
|
60 | (1) |
|
8.6 e-Labelling, Web Sites, Internet, and Social Media: A Brave New World for Labeling |
|
|
61 | (2) |
|
8.7 Language, Language Level and Intended User |
|
|
63 | (1) |
|
|
64 | (3) |
|
9 Clinical Trials: Legal and Ethical Considerations of Increasing Globalization |
|
|
67 | (12) |
|
|
|
67 | (1) |
|
9.2 The Increasing Trend of Offshore Clinical Trials |
|
|
68 | (1) |
|
9.3 International Standards to Protect Patients |
|
|
69 | (1) |
|
9.4 Breaches of Clinical Trial Legality |
|
|
70 | (1) |
|
9.5 Issues of Informed Consent |
|
|
71 | (1) |
|
9.6 Cultural and Social Factors |
|
|
71 | (1) |
|
9.7 Vulnerable Patient Populations |
|
|
72 | (1) |
|
9.8 Economic Considerations |
|
|
72 | (1) |
|
9.9 Comparison of Trial Population to Target Population |
|
|
73 | (2) |
|
|
75 | (4) |
|
10 Regulatory Affairs for Medical Device Clinical Trials in Asia Pacific |
|
|
79 | (22) |
|
|
|
79 | (1) |
|
10.2 Medical Device Clinical Trials versus Pharmaceutical Clinical Trials |
|
|
80 | (3) |
|
10.3 Regulation of Clinical Trials |
|
|
83 | (4) |
|
|
87 | (9) |
|
|
89 | (2) |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
92 | (1) |
|
|
92 | (1) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
96 | (1) |
|
10.5 Moving Ahead as Regulatory Affairs Professionals |
|
|
96 | (5) |
|
11 Medical Device Classification Guide |
|
|
101 | (24) |
|
|
11.1 How to Carry Out Medical Device Classification |
|
|
101 | (2) |
|
|
101 | (1) |
|
|
102 | (1) |
|
11.2 Main Classifications |
|
|
103 | (6) |
|
|
103 | (1) |
|
|
103 | (1) |
|
|
104 | (2) |
|
|
106 | (1) |
|
|
107 | (1) |
|
|
107 | (1) |
|
|
108 | (1) |
|
|
109 | (1) |
|
11.3 Medical Device Classification: Practical Examples |
|
|
109 | (16) |
|
12 ISO 13485:2003 Medical Devices --- Quality Management Systems --- Requirements or Regulatory Purposes |
|
|
125 | (20) |
|
|
|
|
125 | (1) |
|
12.2 Background and Origins of ISO 13485:2003 |
|
|
126 | (2) |
|
12.3 Management Systems Standard |
|
|
128 | (1) |
|
12.4 Quality Management Systems |
|
|
129 | (1) |
|
12.5 ISO 9000 and ISO 13485 Quality Management System Family of Standards |
|
|
130 | (1) |
|
12.6 ISO 13485:2003 and Regulatory Requirements Around the World |
|
|
131 | (1) |
|
12.7 Good Reasons to Implement an ISO 13485: 2003 Quality Management System |
|
|
132 | (1) |
|
|
132 | (1) |
|
12.9 Planning the Implementation |
|
|
133 | (1) |
|
12.10 Scope, Exclusions and Non-Applicability |
|
|
134 | (1) |
|
|
134 | (1) |
|
12.12 Record Completion and Control |
|
|
135 | (1) |
|
12.13 Management Responsibility |
|
|
135 | (1) |
|
12.14 Resource Management |
|
|
136 | (1) |
|
12.15 Product Realisation |
|
|
136 | (1) |
|
|
136 | (1) |
|
12.17 Design and Development |
|
|
137 | (1) |
|
12.18 Purchasing and Supplier Control |
|
|
138 | (1) |
|
12.19 Production and Service Provision |
|
|
138 | (1) |
|
12.20 Monitoring and Measuring, Including Internal Audits and Management Review |
|
|
139 | (1) |
|
12.21 Control of Non-Conforming Product |
|
|
140 | (1) |
|
|
140 | (1) |
|
12.23 Improvement: Corrective Action and Preventive Action |
|
|
140 | (1) |
|
12.24 Purpose and Goal of ISO 13485: 2003 Certification |
|
|
141 | (1) |
|
12.25 Achieving Certification and Continuing to Maintain Certification |
|
|
141 | (4) |
|
13 ISO 14971: Application of Risk Management to Medical Devices |
|
|
145 | (20) |
|
|
|
|
145 | (4) |
|
13.2 The Foundation of a Risk Management (RM] Framework: Policy, Plan, Team, Process, and Documentation |
|
|
149 | (1) |
|
|
149 | (1) |
|
|
149 | (1) |
|
|
149 | (1) |
|
|
150 | (1) |
|
|
150 | (1) |
|
|
150 | (4) |
|
|
150 | (1) |
|
|
151 | (1) |
|
|
151 | (2) |
|
13.3.4 Feedback from Production and Post-Production Information |
|
|
153 | (1) |
|
|
154 | (1) |
|
13.5 Case Study --- An Example to Illustrate Risk Management on a Medical Device: Functional Electrical Stimulation System for Walking |
|
|
154 | (11) |
|
13.5.1 Risk Management Process |
|
|
156 | (9) |
|
PART 3 HARMONIZATION OF MEDICAL DEVICES IN ASIA |
|
|
|
14 Medical Devices in the World Health Organization |
|
|
165 | (4) |
|
Adriana Velazquez Berumen |
|
|
|
15 Asian Harmonization Working Party |
|
|
169 | (4) |
|
|
|
169 | (1) |
|
|
170 | (3) |
|
16 Asia-Pacific Economic Cooperation |
|
|
173 | (10) |
|
|
|
173 | (3) |
|
16.1.1 Trade and Investment Liberalization |
|
|
174 | (1) |
|
16.1.2 Business Facilitation |
|
|
175 | (1) |
|
16.1.3 Economic and Technical Cooperation |
|
|
175 | (1) |
|
16.2 APEC LSIF: Life Sciences Innovation Forum (Reports to Committee on Trade and Investment) |
|
|
176 | (2) |
|
16.3 APEC LSIF/RHSC: Regulatory Harmonization Steering Committee |
|
|
178 | (5) |
|
17 Harmonization of Medical Device in ASEAN |
|
|
183 | (8) |
|
|
|
183 | (1) |
|
17.1.1 Medical Device Market in ASEAN |
|
|
183 | (1) |
|
17.1.2 Medical Device Regulatory Environment in ASEAN |
|
|
184 | (1) |
|
17.2 ASEAN Medical Device Directive and Harmonization |
|
|
184 | (7) |
|
17.2.1 Provisions of the AMDD |
|
|
185 | (1) |
|
17.2.2 Definition of a Medical Device |
|
|
186 | (1) |
|
17.2.3 Medical Device Classification |
|
|
187 | (1) |
|
17.2.4 Common Submission Dossier Template |
|
|
187 | (1) |
|
17.2.5 Post-Market Alert System |
|
|
188 | (1) |
|
|
188 | (1) |
|
17.2.7 Future of ASEAN Harmonization |
|
|
189 | (2) |
|
18 Regulatory Affairs Professionals Society |
|
|
191 | (8) |
|
|
|
|
191 | (1) |
|
18.2 Importance in Today's Global Environment |
|
|
192 | (1) |
|
18.3 The Global Regulatoty Community |
|
|
193 | (1) |
|
18.4 Building Knowledge and Competencies |
|
|
194 | (1) |
|
|
195 | (1) |
|
18.6 Professional Knowledge and Standards |
|
|
196 | (1) |
|
18.7 News and Information |
|
|
197 | (2) |
|
19 Expediting Innovation in Singapore with Regulatory Knowledge |
|
|
199 | (12) |
|
|
|
19.1 The Biodesign Innovation Process |
|
|
201 | (3) |
|
|
202 | (1) |
|
|
202 | (2) |
|
|
204 | (1) |
|
19.2 The Innovator's Resource |
|
|
204 | (3) |
|
|
207 | (4) |
|
PART 4 MEDICAL DEVICE REGULATORY SYSTEM IN THE UNITED STATES AND THE EUROPEAN UNION |
|
|
|
20 United States Medical Device Regulatory Framework |
|
|
211 | (22) |
|
|
|
211 | (2) |
|
20.2 The FDA Center for Devices and Radiological Health |
|
|
213 | (1) |
|
20.3 Total Product Life Cycle Approach |
|
|
213 | (1) |
|
20.4 Legislation and Device Laws |
|
|
214 | (1) |
|
20.4.1 FDA Law vs. FDA Regulations vs. FDA Guidance |
|
|
215 | (1) |
|
20.5 The Regulatory Environment for Bringing a Medical Device to Market |
|
|
215 | (1) |
|
20.6 Regulatory Considerations to Market and Keep Devices in Distribution |
|
|
216 | (13) |
|
20.6.1 Definition of Medical Devices |
|
|
216 | (1) |
|
20.6.2 Classification of Medical Devices |
|
|
217 | (1) |
|
20.6.3 Adulteration and Misbranding |
|
|
218 | (1) |
|
20.6.4 Establishment Registration and Medical Device Listing |
|
|
219 | (1) |
|
20.6.5 Premarket Notification (510(k)) |
|
|
220 | (1) |
|
|
221 | (1) |
|
20.6.5.2 Predicate device and substantial equivalence |
|
|
221 | (2) |
|
20.6.5.3 Planning and assembling the 510(k) submission process |
|
|
223 | (2) |
|
20.6.6 Premarket Approval (PMA) |
|
|
225 | (1) |
|
20.6.7 Investigational Device Exemption (IDE) |
|
|
226 | (1) |
|
|
226 | (1) |
|
20.6.9 Quality System (QS) Regulation/Good Manufacturing Practices (GMP) |
|
|
227 | (1) |
|
20.6.10 Medical Device Reporting (MDR) |
|
|
227 | (1) |
|
|
228 | (1) |
|
|
229 | (4) |
|
21 European Union: Medical Device Regulatory System |
|
|
233 | (42) |
|
|
|
233 | (1) |
|
21.2 Europ'ean Union: History and Structure |
|
|
234 | (1) |
|
21.3 New Approach --- Global Approach Concepts |
|
|
235 | (4) |
|
21.4 Harmonized Standards and Presumption of Conformity |
|
|
239 | (4) |
|
21.5 European Associations |
|
|
243 | (1) |
|
21.6 Overview of Medical Devices Directives |
|
|
243 | (1) |
|
|
244 | (1) |
|
|
245 | (4) |
|
|
245 | (1) |
|
|
245 | (1) |
|
21.8.3 Competent Authority |
|
|
246 | (1) |
|
21.8.4 Notified Body: Conformity Assessment Body |
|
|
247 | (1) |
|
21.8.5 Legal Manufacturer |
|
|
248 | (1) |
|
21.8.6 Authorized Representative |
|
|
249 | (1) |
|
|
249 | (3) |
|
|
249 | (1) |
|
21.9.2 Active Implantable Medical Devices |
|
|
250 | (1) |
|
21.9.3 In vitro and Diagnostics Medical Devices |
|
|
251 | (1) |
|
21.10 Conformity Assessment Procedures |
|
|
252 | (3) |
|
21.11 Essential Requirements |
|
|
255 | (2) |
|
|
257 | (1) |
|
21.13 Technical Documentation |
|
|
258 | (1) |
|
21.14 Quality Management System |
|
|
258 | (6) |
|
|
264 | (1) |
|
21.16 Clinical Evaluation |
|
|
264 | (2) |
|
21.17 CE Mark Certificate and Declaration of Conformity |
|
|
266 | (1) |
|
21.18 Post-Market Surveillance |
|
|
267 | (1) |
|
21.19 Recent Changes of MDD 93/42/EEC and Impacts |
|
|
268 | (2) |
|
|
270 | (1) |
|
21.21 Overview of All Interactions and Key Terminology |
|
|
271 | (4) |
|
22 Regulation of Combination Products in the United States |
|
|
275 | (12) |
|
|
|
|
275 | (1) |
|
22.2 What Products Are Considered Combination Products |
|
|
276 | (1) |
|
22.3 The Standards for Determining If a Product Is a Combination Product |
|
|
276 | (1) |
|
22.4 The Standards for Determining Which FDA Component has Primary Responsibility for Regulating a Combination Product |
|
|
277 | (3) |
|
22.5 Requests for Designation |
|
|
280 | (1) |
|
22.6 Premarket Review Considerations |
|
|
280 | (1) |
|
22.7 Post-Market Regulatory Considerations |
|
|
281 | (1) |
|
22.8 Role of Office of Combination Products |
|
|
282 | (2) |
|
22.9 Near-Term Developments That May Arise in the US |
|
|
284 | (1) |
|
22.10 International Harmonization and Coordination Activities with Foreign Counterparts |
|
|
284 | (1) |
|
22.11 FDA Resources for Obtaining Additional Information |
|
|
285 | (2) |
|
23 Regulation of Combination Products in the European Union |
|
|
287 | (14) |
|
|
|
23.1 Introduction: Legal Basis |
|
|
287 | (4) |
|
|
288 | (1) |
|
|
288 | (1) |
|
23.1.1.2 Medicinal product |
|
|
289 | (1) |
|
23.1.1.3 Combination products: Principal mode of action |
|
|
290 | (1) |
|
23.1.1.4 Borderline products: MEDDEV 2.1/3 |
|
|
291 | (1) |
|
23.1.1.5 Borderline products: Manual of decisions |
|
|
291 | (1) |
|
23.2 Combination Products Regulated as Medicinal Products |
|
|
291 | (1) |
|
23.2.1 Examples of Combination Products Regulated as Medicinal Products |
|
|
292 | (1) |
|
23.3 Combination Products Regulated as Medical Devices |
|
|
292 | (1) |
|
23.3.1 Examples of Combination Products Regulated as Drug-Delivery Devices |
|
|
292 | (1) |
|
23.4 Combination Products Regulated as Devices Incorporating, as an Integral Part, an Ancillary Medicinal Substance |
|
|
293 | (1) |
|
23.4.1 Examples of Devices Incorporating an Ancillary Medicinal Substance |
|
|
293 | (1) |
|
23.4.2 Examples of Drug Substances Incorporated into Devices |
|
|
294 | (1) |
|
23.4.3 Assessment of the Medicinal Substance Aspects of a Device Incorporating an Ancillary Medicinal Substance |
|
|
294 | (1) |
|
23.5 The Consultation Process |
|
|
294 | (1) |
|
23.6 Information to Be Provided on the Ancillary Medicinal Substance |
|
|
295 | (2) |
|
|
295 | (1) |
|
23.6.2 Quality, Safety, Usefulness (Clinical Benefit/Risk) |
|
|
295 | (1) |
|
|
295 | (1) |
|
23.6.2.2 Safety and usefulness (clinical benefit/risk) |
|
|
296 | (1) |
|
|
296 | (1) |
|
23.7 Other Combination Products |
|
|
297 | (4) |
|
PART 5 MEDICAL DEVICE REGULATORY SYSTEM IN ASIA-PACIFIC REGION |
|
|
|
24 Australian Medical Device Regulations: An Overview |
|
|
301 | (16) |
|
|
|
301 | (1) |
|
24.1.1 Medical Device Market in Australia |
|
|
301 | (1) |
|
24.2 Medical Device Regulations |
|
|
302 | (1) |
|
|
302 | (1) |
|
24.2.2 Regulating Authority |
|
|
303 | (1) |
|
24.2.3 Legislation and Guidance |
|
|
303 | (1) |
|
24.3 Definition of Medical Device |
|
|
303 | (1) |
|
24.4 Classification of Medical Devices |
|
|
304 | (2) |
|
24.4.1 Classification of IVD Medical Devices |
|
|
304 | (2) |
|
24.5 Inclusion of Medical Devices on the ARTG |
|
|
306 | (6) |
|
24.5.1 Process for Supplying a Medical Device in Australia |
|
|
306 | (1) |
|
24.5.2 Process for Including Class 1 IVD Medical Devices (Other Than Export Only) in the ARTG |
|
|
307 | (3) |
|
24.5.3 Process for Including IVD Medical Devices (Other Than Class 1) in the ARTG |
|
|
310 | (2) |
|
24.6 Same Kind of Medical Device (SKMD) |
|
|
312 | (1) |
|
24.7 Unique Product Identifier |
|
|
312 | (1) |
|
24.8 In vitro Diagnostic UPIs |
|
|
313 | (1) |
|
|
314 | (1) |
|
24.10 Documentation Requirements |
|
|
314 | (1) |
|
24.10.1 Conformity Assessment Applications |
|
|
314 | (1) |
|
|
315 | (1) |
|
24.12 Access to Unapproved Medical Devices |
|
|
316 | (1) |
|
25 China: Medical Device Regulatory System |
|
|
317 | (14) |
|
|
|
317 | (1) |
|
|
318 | (1) |
|
25.3 Overview of Regulatory Environment and What Laws/Regulations Govern the Medical Devices |
|
|
318 | (2) |
|
25.3.1 Measuring Function |
|
|
319 | (1) |
|
|
319 | (1) |
|
|
320 | (1) |
|
|
321 | (7) |
|
25.5.1 Definition of Medical Device |
|
|
321 | (1) |
|
25.5.2 Classification of Medical Device |
|
|
321 | (1) |
|
25.5.3 Registration Process |
|
|
322 | (1) |
|
25.5.3.1 Medical devices registration certificate |
|
|
322 | (1) |
|
|
323 | (1) |
|
|
324 | (1) |
|
25.5.3.4 Exemption of clinical trial data for Class II devices |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
326 | (1) |
|
|
327 | (1) |
|
25.6 Monitoring Adverse Events |
|
|
328 | (1) |
|
|
329 | (2) |
|
26 Hong Kong: Medical Device Regulatory System |
|
|
331 | (10) |
|
|
|
331 | (1) |
|
26.1.1 Market Environment |
|
|
331 | (1) |
|
26.2 Overview of Regulatory Environment and What Laws/Regulations Govern Medical Devices |
|
|
332 | (1) |
|
|
333 | (2) |
|
|
335 | (4) |
|
26.4.1 Definition of Medical Device (It Follows GHTF) |
|
|
334 | (1) |
|
26.4.2 The Classification of Medical Devices |
|
|
335 | (1) |
|
26.4.3 Role of Distributors or Local Subsidiaries |
|
|
336 | (1) |
|
26.4.4 Product Registration or Conformity Assessment Route and Time Required |
|
|
337 | (1) |
|
26.4.4.1 Suggested registration routes/steps |
|
|
338 | (1) |
|
26.4.4.2 Technical material requirement |
|
|
338 | (1) |
|
26.4.4.3 The labelling requirement of medical device |
|
|
338 | (1) |
|
26.4.4.4 Post-marketing surveillance requirement |
|
|
338 | (1) |
|
26.4.4.5 Manufacturing-related regulation: Do manufacturers need registration/authorization? |
|
|
339 | (1) |
|
26.4.4.6 Clinical trial-related regulation: Are medical device clinical trials regulated? |
|
|
339 | (1) |
|
26.4.4.7 Is there a procedure for mutual recognition of foreign marketing approval or international standards? |
|
|
339 | (1) |
|
|
339 | (1) |
|
|
340 | (1) |
|
27 India: Medical Device Regulatory System |
|
|
341 | (24) |
|
|
|
341 | (11) |
|
27.1.1 Market Environment |
|
|
341 | (1) |
|
27.1.2 Overview of Regulatory Environment and What Laws/Regulations Govern Medical Devices |
|
|
342 | (4) |
|
27.1.3 Functions Undertaken by DCGI and Central Government |
|
|
346 | (1) |
|
27.1.3.1 Statutory functions |
|
|
346 | (1) |
|
|
346 | (1) |
|
27.1.4 Functions Undertaken by the FDA and State Governments |
|
|
347 | (1) |
|
27.1.4.1 Statutory functions |
|
|
347 | (1) |
|
27.1.5 Guidance Documents |
|
|
348 | (1) |
|
27.1.6 Indian Pharmacopoeial Commission |
|
|
349 | (1) |
|
27.1.7 Detail of Key Regulator(s) |
|
|
349 | (3) |
|
|
352 | (9) |
|
27.2.1 Definition of Medical Device |
|
|
352 | (1) |
|
27.2.2 Classification of Medical Device |
|
|
353 | (1) |
|
27.2.3 Role of Distributors or Local Subsidiaries (LRP) |
|
|
353 | (1) |
|
27.2.4 Product Registration or Conformity Assessment Route and Time Required |
|
|
354 | (2) |
|
27.2.5 Quality System Regulation |
|
|
356 | (1) |
|
27.2.6 Product Registration and Quality System Regulation for Combined Device-Drug Product |
|
|
356 | (1) |
|
|
356 | (1) |
|
27.2.8 Technical Material Requirement |
|
|
357 | (1) |
|
27.2.9 The Labelling Requirement of Medical Device |
|
|
358 | (1) |
|
27.2.10 Post-Marketing Surveillance Requirement |
|
|
359 | (1) |
|
27.1.11 Manufacturing-Related Regulation |
|
|
359 | (1) |
|
27.1.12 Clinical Trial-Related Regulation |
|
|
360 | (1) |
|
27.1.13 Is There a Procedure for Mutual Recognition of Foreign Marketing Approval or International Standards? |
|
|
361 | (1) |
|
|
361 | (1) |
|
27.3.1 Any Price Control of Medical Device |
|
|
361 | (1) |
|
27.3.2 Are Parallel Imports Allowed? |
|
|
362 | (1) |
|
27.3.3 Any Advertisement Regulation of Medical Device? |
|
|
362 | (1) |
|
27.4 Upcoming Regulation Changes |
|
|
362 | (1) |
|
27.5 Related Agencies/Departments and Ministries |
|
|
363 | (2) |
|
28 Indonesia: Medical Device Regulatory System |
|
|
365 | (22) |
|
|
|
365 | (2) |
|
28.2 Regulating Authority |
|
|
367 | (1) |
|
28.3 Definition of Medical Device |
|
|
367 | (1) |
|
28.4 Classification of Medical Devices |
|
|
368 | (1) |
|
28.5 Registration of Medical Devices |
|
|
369 | (3) |
|
|
368 | (2) |
|
28.5.2 Documents Required |
|
|
370 | (1) |
|
28.5.3 Official Registration Fee |
|
|
370 | (1) |
|
|
370 | (1) |
|
28.5.5 Validity of Product License |
|
|
371 | (1) |
|
28.5.6 Indonesian Labeling Requirement |
|
|
371 | (1) |
|
28.5.7 Regulatory Action for Changes and Device Modifications |
|
|
371 | (1) |
|
28.6 Post Market Surveillance System |
|
|
372 | (15) |
|
29 Japan: Medical Device Regulatory System |
|
|
387 | (16) |
|
|
|
387 | (1) |
|
29.2 Regulatory Agency in Japan |
|
|
388 | (3) |
|
29.2.1 The Ministry of Health, Labour and Welfare |
|
|
388 | (1) |
|
29.2.2 Pharmaceuticals and Medical Devices Agency |
|
|
388 | (1) |
|
29.2.3 Shared Responsibility of MHLW and PMDA on Medical Device Regulation |
|
|
388 | (3) |
|
29.3 Legislation of Medical Devices |
|
|
391 | (5) |
|
29.3.1 Classification of Medical Devices |
|
|
392 | (1) |
|
29.3.2 Type of Product's Registration |
|
|
393 | (1) |
|
|
393 | (1) |
|
29.3.2.2 Pre-market certification (third-party certification) |
|
|
393 | (1) |
|
29.3.2.3 Pre-market approval |
|
|
394 | (1) |
|
29.3.3 Marketing Authorization Holder |
|
|
394 | (1) |
|
29.3.4 Manufacturer License (Art. 13)/ Accreditation of Foreign Manufacturer (Art. 13-3) |
|
|
394 | (2) |
|
29.4 Related Requirements |
|
|
396 | (1) |
|
29.4.1 Quality Management System |
|
|
396 | (1) |
|
29.4.1.1 QMS conformity as an essential requirement |
|
|
396 | (1) |
|
|
397 | (1) |
|
29.4.2 Good Quality Practices |
|
|
397 | (1) |
|
29.5 MAH'S Obligations during Post-Market Phase |
|
|
397 | (3) |
|
29.5.1 Collection, Analysis and Reporting of Safety Information |
|
|
399 | (1) |
|
|
399 | (1) |
|
29.5.3 Post-Marketing Safety Management |
|
|
400 | (1) |
|
29.6 PMDA's Obligations during Post-Market Phase |
|
|
400 | (3) |
|
|
401 | (1) |
|
29.6.2 Information Services |
|
|
401 | (2) |
|
30 Jordan: Medical Device Regulatory System |
|
|
403 | (18) |
|
|
30.1 Jordan Food and Drug Administration: Introduction |
|
|
403 | (1) |
|
|
403 | (1) |
|
|
404 | (1) |
|
30.1.3 Overview of Structure of Jordan Food and Drug Administration |
|
|
404 | (1) |
|
30.2 Medical Device Market in Jordan |
|
|
404 | (1) |
|
30.3 Overview of Regulatory Environment and What Laws/Regulations Govern the Medical Devices |
|
|
404 | (5) |
|
|
409 | (1) |
|
30.5 Price Control of Medical Device |
|
|
409 | (1) |
|
|
409 | (12) |
|
31 Republic of Korea (South Korea): Medical Device Regulatory System |
|
|
421 | (24) |
|
|
|
421 | (3) |
|
31.1.1 Facts about South Korea |
|
|
421 | (1) |
|
31.1.2 Medical Device Market Scale in South Korea |
|
|
422 | (1) |
|
31.1.3 Definition of Medical Device |
|
|
422 | (1) |
|
31.1.4 Detail of Key Regulator |
|
|
423 | (1) |
|
31.2 Introduction to Korea Medical Device Regulatory System |
|
|
424 | (15) |
|
|
424 | (1) |
|
|
425 | (1) |
|
31.2.3 KGMP: Quality Management System |
|
|
426 | (3) |
|
31.2.4 Product Notification: Class I Devices |
|
|
429 | (1) |
|
31.2.5 Product License: Class II, III, and IV Devices |
|
|
430 | (1) |
|
|
430 | (1) |
|
|
431 | (1) |
|
31.2.8 Device Notification/License |
|
|
432 | (1) |
|
31.2.9 Technical File Review |
|
|
433 | (1) |
|
31.2.10 Type Testing (Mandatory for Class II, III, and IV Devices) |
|
|
434 | (2) |
|
31.2.11 KFDA-Registered 13 Laboratories |
|
|
436 | (1) |
|
31.2.12 Applying for a Product License |
|
|
437 | (1) |
|
|
437 | (1) |
|
31.2.14 Audit of Quality Management System (KGMP Certification) |
|
|
438 | (1) |
|
31.2.15 Post-Market Surveillance System |
|
|
438 | (1) |
|
|
439 | (6) |
|
|
439 | (1) |
|
|
439 | (1) |
|
31.3.3 Import Documentation |
|
|
439 | (1) |
|
|
440 | (1) |
|
31.3.5 Medical Device Advertisements |
|
|
441 | |
|
|
439 | (6) |
|
32 Malaysia: Medical Device Regulatory System |
|
|
445 | (12) |
|
|
|
445 | (1) |
|
32.2 Regulating Authority |
|
|
446 | (1) |
|
32.3 Definition of Medical Device |
|
|
447 | (1) |
|
32.4 Classification of Medical Devices |
|
|
447 | (2) |
|
32.5 Registration of Medical Devices |
|
|
449 | (4) |
|
32.5.1 Market Environment |
|
|
450 | (1) |
|
32.5.2 Conformity Assessment Process |
|
|
451 | (2) |
|
32.5.3 Combination Products |
|
|
453 | (1) |
|
32.6 Post-Market Surveillance and Vigilance |
|
|
453 | (2) |
|
32.6.1 Mandatory Reporting |
|
|
453 | (1) |
|
32.6.2 Field Corrective Action |
|
|
454 | (1) |
|
|
454 | (1) |
|
|
455 | (1) |
|
32.7 Regulatory Action for Changes and Device Modifications |
|
|
455 | (2) |
|
33 Philippines: Medical Device Regulatory and Licensing |
|
|
457 | (12) |
|
|
|
|
457 | (1) |
|
|
458 | (2) |
|
33.3 History of Medical Device Regulation |
|
|
460 | (1) |
|
33.4 Regional Medical Device Harmonization under Development through ASEAN |
|
|
461 | (1) |
|
33.5 Definition of Medical Device in Philippines |
|
|
462 | (1) |
|
33.6 Registration with BEAD |
|
|
463 | (3) |
|
33.6.1 License to Operate |
|
|
463 | (1) |
|
33.6.2 License to Operate: Requirements |
|
|
464 | (1) |
|
33.6.3 Certificate of Product Registration |
|
|
465 | (1) |
|
33.6.4 Certificate of Product Registration: Technical Requirements |
|
|
465 | (1) |
|
33.6.5 Certificate of Product Registration: Legal Requirements |
|
|
466 | (1) |
|
|
466 | (1) |
|
33.8 Import Documentation |
|
|
467 | (1) |
|
33.9 Summary of Regulatory System |
|
|
467 | (1) |
|
|
468 | (1) |
|
34 Saudi Arabia: Medical Device Regulation System |
|
|
469 | (18) |
|
|
|
469 | (1) |
|
34.2 Legislative Responsibilities |
|
|
470 | (1) |
|
34.3 Executive Responsibilities |
|
|
470 | (1) |
|
34.4 Surveillance Responsibilities |
|
|
471 | (1) |
|
|
472 | (1) |
|
34.6 Registration Requirements |
|
|
473 | (1) |
|
34.7 Information to Be Provided to SFDA |
|
|
473 | (3) |
|
34.8 Medical Device Marketing Authorization (MDMA) |
|
|
476 | (2) |
|
34.9 Medical Device Listing |
|
|
478 | (1) |
|
|
478 | (2) |
|
34.11 General Information and Documentary Evidence to Be Provided to SFDA |
|
|
480 | (1) |
|
34.12 Labeling Requirement for Medical Device |
|
|
481 | (1) |
|
34.13 Post-Market Surveillance Requirement |
|
|
481 | (6) |
|
35 Singapore: Medical Device Regulatory System |
|
|
487 | (26) |
|
|
35.1 Market Overview Introduction: An Explanation of the Process and Approach |
|
|
487 | (4) |
|
35.1.1 Market Environment |
|
|
487 | (1) |
|
35.1.2 Overview of Regulatory Environment and What Laws/Regulations Govern Medical Devices |
|
|
488 | (1) |
|
35.1.2.1 Phase I implementation |
|
|
489 | (1) |
|
35.1.2.2 Phase II implementation |
|
|
489 | (1) |
|
35.1.2.3 Phase III implementation |
|
|
489 | (2) |
|
35.2 Detail of Key Regulator(s) |
|
|
491 | (1) |
|
|
492 | (2) |
|
35.3.1 The Definition of Medical Device |
|
|
492 | (1) |
|
35.3.2 Classification of Medical Devices (Classes A, B, C, and D) |
|
|
493 | (1) |
|
|
493 | (1) |
|
|
493 | (1) |
|
|
494 | (1) |
|
|
494 | (2) |
|
|
494 | (1) |
|
|
495 | (1) |
|
|
495 | (1) |
|
|
496 | (1) |
|
|
496 | (1) |
|
35.5 Product Registration and Time Required |
|
|
496 | (3) |
|
35.5.1 Application Process: Product Registration for Higher Risk Medical Devices (Class B, C, and D) |
|
|
496 | (1) |
|
35.5.2 Product Registration for Lower Risk Medical Devices (Class A) |
|
|
497 | (1) |
|
|
498 | (1) |
|
35.6 Product Registration for Combined Device-Drug Product |
|
|
499 | (1) |
|
|
499 | (1) |
|
35.8 Technical Material Requirement |
|
|
499 | (2) |
|
35.9 Labeling Requirement of Medical Devices |
|
|
501 | (1) |
|
35.10 Post-Marketing Surveillance Requirement |
|
|
502 | (1) |
|
35.11 Manufacturing-, Importing-, and Wholesaling - Related Regulation |
|
|
503 | (1) |
|
35.12 Good Distribution Practice for Medical Devices |
|
|
504 | (1) |
|
35.13 Clinical Trial-Related Regulation |
|
|
504 | (1) |
|
|
505 | (1) |
|
|
506 | (1) |
|
35.15.1 Any Price Control of Medical Device |
|
|
506 | (1) |
|
35.15.2 Are Parallel Imports Allowed? |
|
|
506 | (1) |
|
35.15.3 Any Advertisement Regulation of Medical Device? |
|
|
507 | (1) |
|
35.16 Upcoming Regulatory Implementation |
|
|
507 | (6) |
|
35.16.1 Regulatory Framework for Cell- and Tissue-Based Therapeutic Products |
|
|
507 | (6) |
|
36 Taiwan: Medical Device Regulatory System |
|
|
513 | (12) |
|
|
|
513 | (4) |
|
36.1.1 Overview of Structure and Funding of Local Healthcare System |
|
|
513 | (2) |
|
36.1.2 Overview of Regulatory Environment and Laws/Regulations Governing Medical Devices |
|
|
515 | (2) |
|
36.1.3 Detail of Key Regulator(s) |
|
|
517 | (1) |
|
|
517 | (2) |
|
36.2.1 Definition of Medical Device |
|
|
517 | (1) |
|
36.2.2 Classification of Medical Device |
|
|
517 | (1) |
|
36.2.3 Role of Distributors or Local Subsidiaries |
|
|
518 | (1) |
|
36.2.4 Products Registration, Technical Material Requirement, and Time Required |
|
|
518 | (1) |
|
36.3 Quality System Regulation |
|
|
519 | (1) |
|
36.4 Combined Device-Drug Product |
|
|
520 | (1) |
|
|
520 | (1) |
|
36.6 Labeling Requirements of Medical Devices |
|
|
520 | (1) |
|
36.7 Any Post-Marketing Surveillance Requirement |
|
|
521 | (1) |
|
36.8 Manufacturing-Related Regulation |
|
|
521 | (1) |
|
36.9 Clinical Trial-Related Regulation |
|
|
521 | (1) |
|
36.10 International Cooperation |
|
|
522 | (1) |
|
|
522 | (3) |
|
36.11.1 Price Control of Medical Device |
|
|
522 | (1) |
|
|
523 | (1) |
|
36.11.3 Any Advertisement Regulation of Medical Devices? |
|
|
523 | (2) |
|
37 Thailand: Regulatory and Medical Device Control |
|
|
525 | (10) |
|
|
|
525 | (1) |
|
37.2 Medical Device Regulations and Regulators |
|
|
526 | (1) |
|
37.3 Definition of a Medical Device |
|
|
527 | (2) |
|
37.4 Classification of Medical Devices |
|
|
529 | (1) |
|
37.5 Product Registration |
|
|
529 | (3) |
|
37.5.1 Licensed Medical Devices and Notified Medical Devices |
|
|
529 | (1) |
|
37.5.2 General Medical Devices |
|
|
530 | (1) |
|
37.5.3 Review Period (as Promulgated in 2012) |
|
|
531 | (1) |
|
37.5.4 Fees and Validity of Granting or Issued Document |
|
|
532 | (1) |
|
|
532 | (1) |
|
37.7 Advertisement Control |
|
|
533 | (2) |
|
38 UAE: Overview of Medical Device/IVD Regulatory System |
|
|
535 | (12) |
|
|
|
535 | (2) |
|
38.1.1 Registration and Drug Control Department |
|
|
535 | (1) |
|
|
536 | (1) |
|
38.1.3 Medical Device Registration |
|
|
536 | (1) |
|
38.2 Introduction to MD/IVD Regulatory System in UAE |
|
|
537 | (1) |
|
38.3 Medical Devices Marketing Approval Flow Chart |
|
|
538 | (1) |
|
38.4 Approval on Importation Level |
|
|
539 | (1) |
|
38.5 Definition of a Medical Device |
|
|
540 | (1) |
|
38.6 Classification of Medical Device/IVD |
|
|
540 | (1) |
|
38.7 Authorized Representative Concept |
|
|
541 | (1) |
|
38.8 Company Registration |
|
|
542 | (1) |
|
38.8.1 Medical Devices Classified as Nonpharmaceutical Dosage Form |
|
|
542 | (1) |
|
38.8.2 Medical Devices Classified as Containing Pharmaceutical Ingredients |
|
|
543 | (1) |
|
38.9 Product Registration |
|
|
543 | (3) |
|
38.9.1 Medical Devices Subject for Listing |
|
|
543 | (1) |
|
38.9.2 Product Registration: Main Documents |
|
|
544 | (1) |
|
38.9.3 Required Attachments per Device Class |
|
|
545 | (1) |
|
|
546 | (1) |
|
38.11 Parallel Importation |
|
|
546 | (1) |
|
39 Vietnam: Medical Device Regulatory System |
|
|
547 | (8) |
|
|
|
547 | (1) |
|
39.2 Overview of Regulatory Environment and Laws/Regulations Governing Medical Devices |
|
|
548 | (1) |
|
39.2.1 Detail of Key Regulator(s) |
|
|
548 | (1) |
|
|
549 | (1) |
|
39.3.1 Definition of Medical Device |
|
|
549 | (1) |
|
39.4 Classification of Medical Devices (Class A, B, C, D) |
|
|
550 | (1) |
|
39.5 Role of Distributors or Local Subsidiaries |
|
|
550 | (1) |
|
39.6 Product Registration or Conformity Assessment Route and Time Required |
|
|
550 | (3) |
|
39.6.1 Quality System Regulation |
|
|
551 | (1) |
|
39.6.2 Product Registration and Quality System Regulation for Combined Device-Drug Product |
|
|
551 | (1) |
|
|
551 | (1) |
|
39.6.4 Technical Material Requirement |
|
|
552 | (1) |
|
39.6.5 Labeling Requirements for Medical Devices |
|
|
552 | (1) |
|
39.6.6 Post-Marketing Surveillance Requirement |
|
|
552 | (1) |
|
39.6.7 Manufacturing-Related Regulation |
|
|
552 | (1) |
|
39.6.8 Clinical Trial-Related Regulation |
|
|
552 | (1) |
|
39.6.9 Is There a Procedure for Mutual Recognition of Foreign Marketing Approval or International Standards? |
|
|
552 | (1) |
|
|
553 | (1) |
|
39.7.1 Any Control over Prices of Medical Devices? |
|
|
553 | (1) |
|
39.7.2 Are Parallel Imports Allowed? |
|
|
553 | (1) |
|
39.7.3 Any Regulation Regarding Advertisement of Medical Devices? |
|
|
553 | (1) |
|
|
553 | (2) |
Appendix |
|
555 | (20) |
Index |
|
575 | |